MediciNova,Inc. Logo

MediciNova,Inc.

Developing small-molecule drugs for neurology, respiratory, and liver diseases.

4875 | T

Overview

Corporate Details

ISIN(s):
US58468P2065
LEI:
Country:
Japan
Address:
米国カリフォルニア州ラ・ホイヤ、スウィート300、エグゼクティブ・スクエア4275
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

MediciNova, Inc. is a biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for serious diseases with unmet medical needs. The company's primary development efforts are concentrated on neurology, respiratory, and liver diseases. Its pipeline includes candidates such as MN-221, targeting respiratory conditions like acute exacerbations of asthma and COPD, and MN-001 for fibrotic diseases, including liver fibrosis (NASH) and idiopathic pulmonary fibrosis (IPF).

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-12 07:44
Registration Form
確認書
Japanese 8.4 KB
2025-09-12 07:43
Interim Report
半期報告書
Japanese 386.0 KB
2025-06-25 03:32
Regulatory News Service
臨時報告書
Japanese 16.6 KB
2025-06-10 06:52
Audit Report / Information
内部統制報告書
Japanese 51.3 KB
2025-06-10 06:51
Registration Form
確認書
Japanese 12.9 KB
2025-06-10 06:50
Annual Report
有価証券報告書
Japanese 3.0 MB
2024-09-11 04:32
Registration Form
確認書
Japanese 13.0 KB
2024-09-11 04:28
Interim Report
半期報告書
Japanese 436.9 KB
2024-06-17 09:06
Post-Annual General Meeting Information
臨時報告書
Japanese 15.4 KB
2024-06-13 05:03
Registration Form
確認書
Japanese 13.1 KB
2024-06-13 05:02
Quarterly Report
四半期報告書
Japanese 424.9 KB
2024-06-10 09:48
Audit Report / Information
内部統制報告書
Japanese 51.4 KB
2024-06-10 09:46
Audit Report / Information
有価証券報告書
Japanese 3.3 MB
2024-06-10 09:46
Registration Form
確認書
Japanese 12.9 KB
2023-12-12 06:01
Registration Form
確認書
Japanese 13.1 KB

Automate Your Workflow. Get a real-time feed of all MediciNova,Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for MediciNova,Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for MediciNova,Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Biotech firm using enzyme tech for pharma, healthcare, and bioprocess CDMO services.
South Korea
092040
AMICUS THERAPEUTICS, INC. Logo
Develops advanced therapies for rare lysosomal storage disorders.
United States of America
FOLD
AMINOLOGICS CO.,LTD. Logo
Manufactures high-purity chiral amino acids & APIs for pharma, chemical, and food industries.
South Korea
074430
Amneal Pharmaceuticals, Inc. Logo
Develops & commercializes essential medicines: generics, injectables & specialty drugs.
United States of America
AMRX
Amphastar Pharmaceuticals, Inc. Logo
Develops and manufactures complex injectable, intranasal, and inhalation pharmaceutical products.
United States of America
AMPH
Amylyx Pharmaceuticals, Inc. Logo
Developing novel therapies for neurodegenerative diseases like ALS and Wolfram syndrome.
United States of America
AMLX
AN2 Therapeutics, Inc. Logo
Developing novel small molecule drugs for infectious diseases and oncology using boron chemistry.
United States of America
ANTX
Develops approved cannabinoid medicines for pain, epilepsy, and heart failure.
United Kingdom
ANAN
ANAPTYSBIO, INC Logo
Clinical-stage biotech developing immunology therapies for autoimmune and inflammatory diseases.
United States of America
ANAB
Develops qPCR diagnostic kits and robotic automation systems for clinical and research laboratories.
Türkiye
ANGEN

Talk to a Data Expert

Have a question? We'll get back to you promptly.